CASI Pharmaceuticals Inc.

2.22
0.12 (5.71%)
At close: Apr 02, 2025, 3:49 PM
2.21
-0.59%
After-hours: Apr 02, 2025, 07:59 PM EDT
5.71%
Bid 2.08
Market Cap 29.75M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -2.23
PE Ratio (ttm) -1
Forward PE -1.16
Analyst Buy
Ask 2.33
Volume 22,313
Avg. Volume (20D) 15,248
Open 2.20
Previous Close 2.10
Day's Range 2.11 - 2.23
52-Week Range 2.04 - 7.67
Beta 0.40

About CASI

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T inve...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 12, 1996
Employees 176
Stock Exchange NASDAQ
Ticker Symbol CASI
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for CASI stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 170.27% from the latest price.

Stock Forecasts

Earnings Surprise

CASI Pharmaceuticals has released their quartely earnings on Mar 31, 2025:
  • Revenue of $13.36M exceeds estimates by $5.97M, with 94.30% YoY growth.
  • EPS of -0.79 misses estimates by -0.79, with -75.56% YoY decline.
  • Next Earnings Release

    CASI Pharmaceuticals Inc. is scheduled to release its earnings on May 13, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    9 months ago
    +36.49%
    CASI Pharmaceuticals shares are trading higher aft... Unlock content with Pro Subscription
    9 months ago
    -0.83%
    CASI Pharmaceuticals shares are trading higher after the company announced a $15 million private placement financing.